Evotec to advance drug discovery in collaboration with the Crohn’s & Colitis Foundation 10-Jan-2024 By Liza Laws Evotec’s end-to-end integrated research and development platform will be able to advance drug discovery for two drug targets which is why it has joined forces with the Crohn’s & Colitis Foundation.
Synthetic Biologics enlists vendor to accelerate enrollment in IBS trial 11-Nov-2019 By Nick Taylor Synthetic Biologics brings third party on board to reach more potential participants in slow enrolling irritable bowel disease (IBS) clinical trial.
IBS treatment market growing at CAGR of 10% to 2026 02-Aug-2019 By Ben Hargreaves The IBS treatment market will develop to be worth $3.3bn by 2026, driven by increased uptake of small molecule treatments and growing incidence.